ADVERTISEMENT
ADVERTISEMENT

Diverse Pharmacological Modulators

For Targets, Pathways and Processes

AMSbio

AMSBIO has announced the launch of PATHM2 small molecules libraries for small scale screening in developmental biology and discovery research.

PATHM2 libraries are available to identify accessory molecules that improve cell viability, proliferation or yields. All compounds are hand selected to address ‘traditional’ cascades that play a role in pluripotency maintenance or specific differentiation. Multiple agents are included to interrogate new and emerging networks/targets relevant to stem cell biology.

PATHM2 kits are also available to screen your disease model and identify/confirm critical pathways and targets. Using PATHM2 kits you will be able to find disease state modulators as starting points for further refinement. All small molecule compounds in the kits have drug/lead-like properties, good water solubility, bio-membrane permeability, activity/selectivity profile and potential for optimization. AMSBIO also provide one-stop scale-up, medicinal chemistry, screening and development services.

In addition, PATHM2 kits can be used to study selected signaling pathways of interest. Custom...

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT